Acute promyelocytic leukemia (APL) is rare in patients with Down syndrome (DS). Cytotoxic chemotherapy combined with all-trans retinoic acid (ATRA) has been a standard treatment for APL, but is potentially intolerable for DS patients because of their vulnerability to cytotoxic agents. We report here a case of a 10-year-old girl with DS and APL successfully treated with a combination of ATRA and arsenic trioxide, a therapy emerging as a new standard for APL. She achieved molecular remission and completed the therapy without significant toxicities. ATRA/arsenic trioxide combination therapy would be a preferable option for DS patients with APL.
Children’s Cancer Center, National Center for Child Health and Development, Tokyo, Japan
Off-label use/unapproved drugs or products: the manuscript includes off-label use of all-trans retinoic acid and arsenic trioxide.
The authors declare no conflict of interest.
Reprints: Daisuke Tomizawa, MD, PhD, Division of Leukemia and Lymphoma, Children’s Cancer Center, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan (e-mail: email@example.com).
Received November 10, 2018
Accepted January 9, 2019